1. Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.170
Figure 3 Effect of dapagliflozin on maximum renal glucose reabsorption (TmG) and glucose threshold
Figure 3 | Effect of dapagliflozin on maximum renal glucose reabsorption (TmG) and glucose threshold. a | In individuals with type 2 diabetes mellitus (T2DM) the TmG is significantly increased in normal glucose tolerant (NGT) individuals and similarly reduced by dapagliflozin in both groups. b | In patients with T2DM the renal threshold for glucose spillage is significantly increased compared to NGT individuals and reduced to less than 2.2 mmol/l (40 mg/dl) in both groups following dapagliflozin treatment. This effect explains why SGLT2 inhibitors produce marked glucosuria in non-diabetic individuals with a normal fasting plasma glucose concentration. Modified with permission from DeFronzo, R. A. et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36, 3169–3176 (2013). Copyright and all rights reserved. Material from this publication has been used with the permission of the American Diabetes Association.
Modified with permission from DeFronzo, R. A. et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36, 3169–3176 (2013). Copyright and all rights reserved. Material from this publication has been used with the permission of the American Diabetes Association.
DeFronzo, R. A. et al. (2016) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Nat. Rev. Nephrol. doi: /nrneph